All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
8 results for "Cancer" and "Gynecologic Cancers" and "Multiple Myeloma"
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Phase 1, Multi-Center, Open-Label, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma
To determine the safety and tolerability of CC-92328 in subjects with R/R MM. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-92328 in subjects with R/R MM.
Protocol No
CELGENE-CC-92328-MM-001
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol No
TENEOBIO-TNB-383B
Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination with Monoclonal Antibodies in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma.
Protocol No
TAKEDA-TAK-981-1503
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies
To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of oral LOXO-338 in patients with previously treated advanced hematologic malignancies.
Protocol No
LOXO-BCL-20001
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
Daratumumab is a human monoclonal antibody or protein drug. An antibody is something that finds and kills foreign cells and organisms in your body, in this case, myeloma cells.
Protocol No
JANSSEN-64407564MMY1002
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Protocol No
GENMAB-GCT3014-01
A Multi-Center, Open Label Phase 1/2 Study of Cyt-0851, an Oral Rad51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639